From Boom to Bust: AFFY's Post-Recall Slide Continues

Boggs, Jennifer
May 2013
BioWorld Today;5/13/2013, Vol. 24 Issue 91, p1
The article focuses on Affymax Inc. based in Palo Alto, California which will end operation by June 15, 2013 based on its 10-Q filing. It discusses the financial impact of the recall of its Omontys (peginesatide), an erythropoiesis stimulating agent approved in 2012 for use in adult dialysis patients with chronic kidney disease, and prospects of restructuring efforts with its partner Takeda Pharmaceutical Co. Ltd. for the drug.


Related Articles

  • Three deaths sink Affymax. DeFrancesco, Laura // Nature Biotechnology;Apr2013, Vol. 31 Issue 4, p270 

    The article reports that the biotech firm Affymax Inc. and its partner Takeda Pharmaceutical Co. Ltd. has stops the dosage and application of the peptide erythropoietin mimetic Omontys and due to its19 serious hypersensitivity reactions, including three deaths.

  • Omontys to Treat Anemia.  // MPR - Urologists' Edition;Spring/Summer2012, Vol. 9 Issue 1, pA.12 

    The article offers brief information on the synthetic PEGylated compound called Omontys, showed to treat anemia, from Affymax Inc. and Takeda Pharmaceuticals Co. Ltd.

  • OTHER NEWS TO NOTE.  // BioWorld Today;3/11/2010, Vol. 21 Issue 47, p2 

    This section offers news briefs on the biotechnology industry. Affymax Inc. received a payment from Takeda Pharmaceutical Co. as part of its global agreement to develop and commercialize Hematide, a treatment for anemia in chronic renal failure patients. The U.S. Food and Drug Administration...

  • Clinic Roundup.  // BioWorld Today;11/6/2012, Vol. 23 Issue 216, p6 

    This section offers news briefs on clinical trials. Positive results were obtained by Aerie Pharmaceuticals Inc. from its Phase II a study of AR-13324 in patients with glaucoma. A post-hoc subgroup analyses of peginesatide for injection studies was disclosed by Affymax Inc. and Takeda...

  • Affymax Crashes on Omontys Recall, Hypersensitivity Data. Boggs, Jennifer // BioWorld Today;2/26/2013, Vol. 24 Issue 37, p1 

    The article reports on the announcement made by Affymax Inc. and partner Takeda Pharmaceutical Co. Ltd. that they were voluntarily withdrawing all lots of erythropoiesis-stimulating agent (ESA) Omontys due to reports of mild allergic reactions. It says that the drug is Affymax's primary growth...

  • Other News To Note.  // BioWorld Today;4/12/2013, Vol. 24 Issue 70, p5 

    This section offers biopharmaceutical news briefs as of April 2013. Affymax Inc. and Takeda Pharmaceutical Co. Ltd. have reached a fourth amendment to their collaboration for Omontys. Boston Therapeutics Inc. has filed for an investigational new drug application (IND) for the drug PAZ320....

  • TOP STORIES.  // MondayMorning;9/1/2008, Vol. 16 Issue 34, p1 

    The article reports updates pharmaceutical industry in the U.S. King Pharmaceuticals Inc. acquires Alpharma Inc. for $1.4 billion to expand its pain treatment offerings. Amylin Pharmaceuticals Inc. fell in Nasdaq Stock Market trading after patients died due to Byetta. Affymax Inc. and Takeda...

  • Affymax Reports 3rd Qtr 2011 Financial Results.  // Biomedical Market Newsletter;11/14/2011, Vol. 21, p1117 

    The article reports on the 3rd quarter financial results of Affymax Inc. ended September 30, 2011. It notes that the net loss of the company for the quarter was 9.8 million (mln) compared to a net loss of 12.0 mln for the same quarter in 2010. It further mentions that the decrease in revenue in...

  • Affymax(r) Receives $10 Mln Milestone Payment for FDA Filing of New Drug Application for Hematide(tm)/Peginesatide.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p330 

    The article reports that a 10 million dollars development milestone payment was received by Affymax Inc. from Takeda Pharmaceutical Co. Ltd. It says that the acceptance and filing of the New Drug Application for peginesatide by the U.S. Food and Drug Administration (FDA) have triggered the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics